Doxercalciferol Injection, Solution
NDC Package 68083-359-50
Package Information
Doxercalciferol injection is a medication used to treat people with serious kidney disease on dialysis who have high levels of a certain substance (parathyroid hormone-PTH), which your body normally makes. This formulation utilizes a injection, solution delivery system. Marketed by Gland Pharma Limited, this product is identified by NDC 68083-359 and is authorized under FDA application ANDA210452.
Identification & Billing
- RxCUI: 1790219 - doxercalciferol 4 MCG in 2 ML Injection
- RxCUI: 1790219 - 2 ML doxercalciferol 0.002 MG/ML Injection
- RxCUI: 1790219 - doxercalciferol 4 MCG per 2 ML Injection
- RxCUI: 282609 - doxercalciferol 2 MCG/ML Injectable Solution
- RxCUI: 282609 - doxercalciferol 0.002 MG/ML Injectable Solution
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 68083 - Gland Pharma Limited
- 68083-359 - Doxercalciferol
- 68083-359-50 - 50 VIAL, MULTI-DOSE in 1 CARTON / 2 mL in 1 VIAL, MULTI-DOSE (68083-359-01)
- 68083-359 - Doxercalciferol
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 68083-359-50 identifies a specific commercial package of 50 vial, multi-dose in 1 carton / 2 ml in 1 vial, multi-dose (68083-359-01) of Doxercalciferol, a human prescription drug labeled by Gland Pharma Limited. This injection, solution is formulated for intravenous use and contains doxercalciferol as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Gland Pharma Limited on September 26, 2019. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used to treat people with serious kidney disease on dialysis who have high levels of a certain substance (parathyroid hormone-PTH), which your body normally makes. High PTH levels affect the balance of other minerals in your body (calcium and phosphorus) and may cause weak bones. Doxercalciferol is a form of vitamin D. It works by decreasing PTH levels and increasing calcium/phosphorus levels in the body.
How is this Gland Pharma Limited product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 68083035950. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.